Summit Therapeutics Inc. Operating Expense
Summit Therapeutics Inc. (SMMT) reported Operating Expense of GBP 10.27 million for the 3-month period ending 2020-03-31, per its 6-K filed 2020-06-02.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:OperatingExpense · last filed 2020-06-02
- Summit Therapeutics Inc. operating expense for the quarter ending 2020-03-31 was 10.27M GBP, a 3.48% increase year-over-year.
- Summit Therapeutics Inc. operating expense for the quarter ending 2019-10-31 was 11.59M GBP, a 9.79% decline year-over-year.
- Summit Therapeutics Inc. operating expense for the quarter ending 2019-07-31 was 10.42M GBP, a 35.55% decline year-over-year.
- Summit Therapeutics Inc. operating expense for the quarter ending 2019-04-30 was 9.93M GBP, a 28.67% decline year-over-year.
| Period end | Operating Expense 3 month | Operating Expense 3 month as first filed | Operating Expense 6 month | Operating Expense 9 month | Operating Expense 9 month as first filed | Operating Expense 11 month | Operating Expense 12 month | Operating Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2020-03-31 | 10.27M GBP 6-K · filed 2020-06-02 | |||||||
| 2019-12-31 | 41.08M GBP 20-F · filed 2020-04-30 | |||||||
| 2019-10-31 | 11.59M GBP 6-K · filed 2019-12-17 | 22.01M GBP derived: sum of 2 quarters · filed 2019-12-17 | 31.94M GBP 6-K · filed 2019-12-17 | |||||
| 2019-07-31 | 10.42M GBP 6-K · filed 2019-10-11 | 20.35M GBP 6-K · filed 2019-10-11 | ||||||
| 2019-04-30 | 9.93M GBP 6-K · filed 2019-06-12 | |||||||
| 2019-03-31 | 11.06M GBP 6-K · filed 2020-06-02 | |||||||
| 2019-01-31 | 12.56M GBP derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | 25.41M GBP derived: sum of 2 quarters · filed 2020-04-30 | 41.58M GBP derived: sum of 3 quarters · filed 2020-04-30 | 55.49M GBP 20-F · filed 2020-04-30 | 55.50M GBP 20-F · filed 2019-03-29 | |||
| 2018-10-31 | 12.85M GBP 6-K · filed 2019-12-17 | 12.85M GBP 6-K · filed 2018-12-11 | 29.02M GBP derived: sum of 2 quarters · filed 2019-12-17 | 42.94M GBP 6-K · filed 2019-12-17 | 42.94M GBP 6-K · filed 2018-12-11 | 57.88M GBP derived: sum of 4 quarters · filed 2020-04-30 | ||
| 2018-07-31 | 16.17M GBP 6-K · filed 2019-10-11 | 16.16M GBP 6-K · filed 2018-09-20 | 30.09M GBP 6-K · filed 2019-10-11 | 45.03M GBP derived: sum of 3 quarters · filed 2020-04-30 | 54.43M GBP derived: sum of 4 quarters · filed 2020-04-30 | |||
| 2018-04-30 | 13.92M GBP 6-K · filed 2019-06-12 | 13.92M GBP 6-K · filed 2018-06-05 | 28.86M GBP derived: sum of 2 quarters · filed 2020-04-30 | 38.27M GBP derived: sum of 3 quarters · filed 2020-04-30 | 47.36M GBP derived: sum of 4 quarters · filed 2020-04-30 | |||
| 2018-01-31 | 14.94M GBP derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | 24.35M GBP derived: sum of 2 quarters · filed 2020-04-30 | 33.45M GBP derived: sum of 3 quarters · filed 2020-04-30 | 40.91M GBP 20-F · filed 2020-04-30 | 40.97M GBP 20-F · filed 2018-04-13 | |||
| 2017-10-31 | 9.41M GBP 6-K · filed 2018-12-11 | 18.50M GBP derived: sum of 2 quarters · filed 2018-12-11 | 25.97M GBP 6-K · filed 2018-12-11 | |||||
| 2017-07-31 | 9.10M GBP 6-K · filed 2018-09-20 | 16.57M GBP 6-K · filed 2018-09-20 | ||||||
| 2017-04-30 | 7.47M GBP 6-K · filed 2018-06-05 | |||||||
| 2017-01-31 | 27.23M GBP 20-F · filed 2019-03-29 | |||||||
| 2016-01-31 | 21.63M GBP 20-F · filed 2018-04-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |